Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Natera - The Real Truth

2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Natera Buys Foresight To Boost Super-Early Cancer Detection Tech

Natera Buys Foresight To Boost Super-Early Cancer Detection Tech

Natera, Inc. (NASDAQ:NTRA) on Friday acquired Foresight Diagnostics, a cancer diagnostics company, for $275 million upfront with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones.

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This

Cathie Wood’s strategy thrives on innovation, and in 2025, Natera could be the purest expression of that conviction.

Bay Area tech and biotech layoffs worsen, Microsoft slashes more jobs

Tech and biotech layoffs have worsened in the Bay Area, a fresh round of cutbacks resulting from job cuts at tech titan Microsoft and genetic testing firm Natera, according to official state government filings.

Tribune News Service

This Diagnostic Testing Company Down 60% - Time to Buy?

Despite witnessing double-digit revenue growth in the last reported quarter Natera Inc. (NTRA) stock has plunged nearly 60% year-to-date. So, let’s evaluate if it is worth buying the stock now. Read on.

8 Analysts Have This to Say About Natera

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

Earnings Preview For Natera

Earnings Preview For Natera

Natera (NASDAQ:NTRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Natera will report an earnings per share (EPS) of $-1.48.

Analyst Ratings for Natera

Analyst Ratings for Natera

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

$100 Invested In Natera 5 Years Ago Would Be Worth This Much

$100 Invested In Natera 5 Years Ago Would Be Worth This Much

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 22.16% on an annualized basis.

Check Out What Whales Are Doing With NTRA

Check Out What Whales Are Doing With NTRA

A whale with a lot of money to spend has taken a noticeably bearish stance on Natera. Looking at options history for Natera (NASDAQ:NTRA) we detected 39 strange trades.

So What's Happening With Natera Shares?

So What's Happening With Natera Shares?

Natera Inc (NASDAQ: NTRA) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company following a Hindenburg Research short

Analyst Ratings For Natera

Over the past 3 months, 4 analysts have published their opinion on Natera (NASDAQ:NTRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Natera: Q4 Earnings Insights

Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera missed estimated earnings by 12.98%, reporting an EPS of $-1.48 versus an estimate of $-1.31.

Natera's Debt Overview

Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Advanced Micro Devices

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play